Payment overview · 2025
General Payments
$539.05
21 reported records · 13 companies
Healthcare provider profile · identity verified
Christopher L Nevins, MD
Allopathic & Osteopathic Physicians|Internal Medicine · HOUSTON, TX · NPI 1376520841
Verified facts
What the public records show
CMS Open Payments records show Christopher L Nevins, MD received $539.05 in general payments during 2025 across 21 reported records.
Merck Sharp & Dohme LLC accounted for 26.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 16 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Linzess.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 21 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 157 claims for Synthroid by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 36 claims for Myrbetriq by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 45 claims for Ozempic by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $142.73 | 26.5% | 3 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $84.91 | 15.8% | 4 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $52.45 | 9.7% | 2 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $41.84 | 7.8% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $38.90 | 7.2% | 2 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $29.50 | 5.5% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $27.21 | 5.0% | 1 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $25.36 | 4.7% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $22.93 | 4.2% | 1 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $22.05 | 4.1% | 1 | 2025 |
| Optinose US, Inc. | Unresolved — no canonical attribution shown | $20.19 | 3.8% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.74 | 2.9% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $15.24 | 2.8% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $539.05 | 21 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $142.73 | 3 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $84.91 | 4 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $52.45 | 2 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $41.84 | 2 | 2025 |
Source payment records
|
|||||
| CREON Normalized: creon |
Drug | ABBVIE INC. | $38.90 | 2 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $38.90 | 2 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $30.96 | 2 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $29.50 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $27.21 | 1 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $25.36 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $22.93 | 1 | 2025 |
Source payment records
|
|||||
| MYFEMBREE Normalized: myfembree |
Drug | Sumitomo Pharma America, Inc. | $22.05 | 1 | 2025 |
Source payment records
|
|||||
| Xhance Normalized: xhance |
Drug | Optinose US, Inc. | $20.19 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.74 | 1 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $15.24 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $15.24 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| LINZESS linzess |
2025 | Linzess | 2024 | 21 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
21 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
157 | 38 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
36 | 12 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
45 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Rosuvastatin Calcium | Rosuvastatin Calcium | 510 | 139 |
| Levothyroxine Sodium | Levothyroxine Sodium | 461 | 119 |
| Atorvastatin Calcium | Atorvastatin Calcium | 322 | 96 |
| Ezetimibe | Ezetimibe | 270 | 76 |
| Sertraline Hcl | Sertraline Hcl | 208 | 42 |
| Azithromycin | Azithromycin | 173 | 131 |
| Amlodipine Besylate | Amlodipine Besylate | 163 | 48 |
| Synthroid | Levothyroxine Sodium | 157 | 38 |
| Zolpidem Tartrate | Zolpidem Tartrate | 155 | 41 |
| Celecoxib | Celecoxib | 148 | 39 |
| Valsartan | Valsartan | 138 | 38 |
| Metoprolol Succinate | Metoprolol Succinate | 120 | 35 |
| Methylprednisolone | Methylprednisolone | 107 | 70 |
| Meloxicam | Meloxicam | 104 | 21 |
| Metformin Hcl | Metformin Hcl | 104 | 30 |
| Losartan Potassium | Losartan Potassium | 102 | 30 |
| Potassium Chloride | Potassium Chloride | 92 | 26 |
| Furosemide | Furosemide | 91 | 23 |
| Alprazolam | Alprazolam | 88 | 35 |
| Irbesartan | Irbesartan | 85 | 24 |
| Allopurinol | Allopurinol | 74 | 20 |
| Hydrochlorothiazide | Hydrochlorothiazide | 70 | 19 |
| Omeprazole | Omeprazole | 70 | 21 |
| Finasteride | Finasteride | 69 | 22 |
| Pantoprazole Sodium | Pantoprazole Sodium | 69 | 21 |
| Nebivolol Hcl | Nebivolol Hcl | 68 | 20 |
| Tamsulosin Hcl | Tamsulosin Hcl | 68 | 26 |
| Mounjaro | Tirzepatide | 67 | suppressed |
| Prednisone | Prednisone | 67 | 49 |
| Repatha Sureclick | Evolocumab | 65 | 11 |
| Pravastatin Sodium | Pravastatin Sodium | 64 | 19 |
| Escitalopram Oxalate | Escitalopram Oxalate | 63 | 13 |
| Lisinopril | Lisinopril | 59 | 19 |
| Donepezil Hcl | Donepezil Hcl | 55 | 12 |
| Duloxetine Hcl | Duloxetine Hcl | 55 | 11 |
| Gabapentin | Gabapentin | 55 | 18 |
| Tramadol Hcl | Tramadol Hcl | 55 | 16 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 53 | 39 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 53 | 14 |
| Pioglitazone Hcl | Pioglitazone Hcl | 53 | 14 |
| Spironolactone | Spironolactone | 53 | 15 |
| Simvastatin | Simvastatin | 52 | 15 |
| Ibandronate Sodium | Ibandronate Sodium | 51 | 16 |
| Xarelto | Rivaroxaban | 51 | 12 |
| Estradiol | Estradiol | 48 | 20 |
| Bupropion Xl | Bupropion Hcl | 47 | 15 |
| Clopidogrel | Clopidogrel Bisulfate | 47 | 11 |
| Montelukast Sodium | Montelukast Sodium | 47 | 16 |
| Ozempic | Semaglutide | 45 | suppressed |
| Eliquis | Apixaban | 44 | 16 |
| Levofloxacin | Levofloxacin | 44 | 35 |
| Eszopiclone | Eszopiclone | 42 | 11 |
| Januvia | Sitagliptin Phosphate | 42 | 12 |
| Trazodone Hcl | Trazodone Hcl | 42 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 41 | 14 |
| Farxiga | Dapagliflozin Propanediol | 41 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 41 | suppressed |
| Cefdinir | Cefdinir | 40 | 33 |
| Propranolol Hcl Er | Propranolol Hcl | 40 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 38 | 11 |
| Carvedilol | Carvedilol | 36 | suppressed |
| Myrbetriq | Mirabegron | 36 | 12 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 35 | 29 |
| Diazepam | Diazepam | 35 | 11 |
| Methocarbamol | Methocarbamol | 35 | 14 |
| Nifedipine Er | Nifedipine | 33 | 11 |
| Clonazepam | Clonazepam | 31 | 11 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 30 | suppressed |
| Temazepam | Temazepam | 30 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 29 | suppressed |
| Cephalexin | Cephalexin | 28 | 24 |
| Premarin | Estrogens, Conjugated | 28 | suppressed |
| Mirtazapine | Mirtazapine | 27 | suppressed |
| Pregabalin | Pregabalin | 27 | suppressed |
| Zaleplon | Zaleplon | 25 | suppressed |
| Ramipril | Ramipril | 24 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 24 | suppressed |
| Colesevelam Hcl | Colesevelam Hcl | 23 | suppressed |
| Ipratropium Bromide | Ipratropium Bromide | 23 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 22 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 22 | suppressed |
| Linzess | Linaclotide | 21 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 21 | suppressed |
| Telmisartan | Telmisartan | 21 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 20 | suppressed |
| Atenolol | Atenolol | 20 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 20 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 20 | 20 |
| Testosterone Cypionate | Testosterone Cypionate | 20 | suppressed |
| Valacyclovir | Valacyclovir Hcl | 20 | 12 |
| Fludrocortisone Acetate | Fludrocortisone Acetate | 19 | suppressed |
| Buspirone Hcl | Buspirone Hcl | 18 | suppressed |
| Fluticasone Propionate | Fluticasone Propionate | 18 | suppressed |
| Niacin Er | Niacin | 18 | suppressed |
| Ondansetron Odt | Ondansetron | 18 | 11 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 18 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 17 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 17 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 17 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 17 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 17 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 17 | suppressed |
| Guanfacine Hcl | Guanfacine Hcl | 16 | suppressed |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 16 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 16 | suppressed |
| Vascepa | Icosapent Ethyl | 16 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 15 | suppressed |
| Betamethasone Dipropionate | Betamethasone Dipropionate | 15 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 15 | suppressed |
| Hydrocortisone | Hydrocortisone | 14 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 13 | suppressed |
| Nadolol | Nadolol | 13 | suppressed |
| Tirosint | Levothyroxine Sodium | 13 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Lidocaine | Lidocaine | 12 | suppressed |
| Memantine Hcl | Memantine Hcl | 12 | suppressed |
| Raloxifene Hcl | Raloxifene Hcl | 12 | suppressed |
| Trulicity | Dulaglutide | 12 | suppressed |
| Acetazolamide | Acetazolamide | 11 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 11 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 11 | suppressed |
| Famotidine | Famotidine | 11 | suppressed |
| Jardiance | Empagliflozin | 11 | suppressed |
| Livalo | Pitavastatin Calcium | 11 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 11 | suppressed |
| Paxlovid (Eua) | Nirmatrelvir/Ritonavir | 11 | 11 |
| Qnasl | Beclomethasone Dipropionate | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $539.05 · 21 records | Merck Sharp & Dohme LLC | CAPVAXIVE, CREON, Cologuard Collection Kit, GARDASIL 9, INSPIRE, Kerendia, LEQVIO, LINZESS, MYFEMBREE, OTEZLA, REPATHA, Tymlos, Veozah, Wegovy, Xhance, ZENPEP | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Linzess play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error